Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Therapeutics Stands to Gain $300,000 in Stock-Purchase Warrant Placed With Lender

This article corrects an earlier version that reported that Lynx had sold $300,000 worth of shares to Silicon Valley Bank. In fact, the company issued a warrant for the bank to buy the stock.

 

NEW YORK, Jan. 25 (GenomeWeb News) - Lynx Therapeutics stands to gain $300,000 from a stock-purchase warrant issued to Silicon Valley Bank, according to a Jan. 3 SEC filing.

 

The warrant gives the bank the option to buy 95,541 shares at $3.14 a piece between Dec. 28, 2004, and Dec. 27, 2007. It is part of the bank's agreement earlier this month to give Lynx a $3 million bridge loan.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.